Company news
Decision Diagnostics Corp (OTC:DECN) news
Decision Diagnostics Corp news releases on 6ix. Latest, Feb 24, 2021: DECN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Decision Diagnostics…
Press releases & updates
DECN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Decision Diagnostics Corp. Investors of Class Action and Encourages Shareholders to Contact the Firm
February 24, 2021
CLASS ACTION UPDATE for DECN, BTBT and AZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
February 9, 2021
BREAKING ALERT: ROSEN, A LEADING LAW FIRM, Encourages Decision Diagnostics Corp. Investors with Large Losses to Secure Counsel Before Important Deadline – DECN
January 30, 2021
Lawsuits Filed Against DECN, BTBT and JFU - Jakubowitz Law Pursues Shareholders Claims
January 24, 2021
Shareholder Alert: Robbins LLP Announces That Decision Diagnostics Corp. (DECN) is Being Sued for Misleading Shareholders
January 21, 2021
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of NAK, KNDI and DECN
January 18, 2021
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Decision Diagnostics Corp. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
January 18, 2021
ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Decision Diagnostics Corp. – DECN
January 18, 2021
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Decision Diagnostics Corp. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
January 16, 2021
DECN to Announce Various Testing Results This Week for Its COVID-19 GenViro! Swift Kit
December 20, 2020
DECN Comments on Recent Legal Filings by Federal Agencies
December 17, 2020
INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims Against Decision Diagnostics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm
December 18, 2020
DECN EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Decision Diagnostics Corp. – DECN
December 18, 2020
DECN Provides Testing Update for US, Korea and XPRIZE With Plans for Walk-in Donor Study for at-Home GenViro! Saliva Swift :10 Test Kit
December 15, 2020
DECN Secures Exclusive Distributor Agreement With a German Based Company for the Distribution of Genviro! Covid-19 :10 Saliva Testing Kits and Meters in 18 EU Countries, Norway and the UK
December 9, 2020
DECN Announces Significant Agreement With Russian Federation Partner for Genviro! and Genviro! Pro COVID-19 Testing Kits as Well as Its Venerable GenUltimate! Blood Glucose Products
November 30, 2020
DECN XPRIZE Testing Data for Rapid COVID-19 Testing Technology Yields Near Textbook Results
November 22, 2020
DECN GenViro! Trial Using Human Saliva Donors for Its Swift Test Kits Proceeds Directly to FDA Level Testing As COVID-19 Product Testing Enters “Home Stretch”
November 11, 2020
DECN Continues to Add GenViro! Dealers With an Agreement Covering Puerto Rico, the Dominican Republic, the US Virgin Islands and Geographies Across the Caribbean and Central America
November 5, 2020
DECN Announces Additional Distribution Agreement With a Distributor and Dealers in Nigeria, Ivory Coast and Lebanon
November 2, 2020
DECN Announces Commencement of US-Based Donor Study for FDA EUA Guidance Testing for Their 10.5 Second Genviro! Saliva Swift COVID-19 Test Kits
October 18, 2020
DECN Provides Progress Update on Major Events for Its GenViro! Saliva Swift Kits for the Detection of COVID-19
October 12, 2020
DECN Enters into a New 6 Month $300,000 Promissory Note with Major Current Investor to Help Fund the Recent International Launch if its GenViro! Swift Kits
October 4, 2020
DECN Receives Significant Initial Order for International GenViro! Saliva Swift Kits for the Detection of COVID-19
October 1, 2020
DECN Signs Agreement With US-Based Laboratory as Testing Partner for Genviro! Saliva Swift Kit Testing for Additional FDA, EU CE Mark and Russian Federation Submissions
September 29, 2020
DECN Announces Completion of Critical Instructional Videos for its GenViro! Saliva Swift Kit for USA and International Professional Use
September 21, 2020
DECN Announces Finalizing of International Genviro! COVID-19 Saliva Swift Kits for Global Market and Establishes Introductory Sales Pricing
September 17, 2020
DECN to Launch Its International Version GenViro! Saliva Swift :10.5 Second Covid-19 Kits on September 26, Will Then Accept Orders from Its Asian Distributor
August 31, 2020
DECN Provides Update on Accomplishments and Pathway to Securing FDA EUA Approval for its COVID-19 "Transmission Indicating Testing" Methodology
August 25, 2020
DECN CEO Releases Open Letter on FDA At-Home COVID-19 Rapid Testing Guidelines Saying It's the Speed to Results Reporting and Certain Added Regulations That Need to Be Addressed
August 9, 2020
DECN Publicly Disavows Covid-19 Swift Kit Video as Produced by Outside Unauthorized Party
August 6, 2020
DECN Issues Support for Recently Announced FDA COVID-19 At-Home Testing Template as the Company's Submission for Its Genviro! Swift COVID-19 At-Home Test Kit Anticipated Many of the New FDA Requisites
August 2, 2020
DECN Readies its GenViro! Covid-19 Swift Kits for Latest FDA Mandated Testing of both Saliva and Blood Protocols as it Enters Final Selection Process for a U.S. Based Testing Partner
July 22, 2020
DECN Says its Newest GenViro! COVID-19 Swift Kit Saliva Testing Option Can Play an Extensive Role in the Re-Opening of Schools as Company Awaits FDA Authorization
July 16, 2020
DECN to add GenViro! Saliva Covid-19 Swift Kit :10.5 for Professional and Home Use Testing, Providing an Alternative Modality to its Finger Stick Methodology
July 9, 2020
DECN Announces Distribution Agreement Covering GenViro! Covid-19:10.5 Swift Kits and Its GenUltimate and TGB Products in India, Malaysia, Sri Lanka, Singapore, Indonesia, Thailand, Vietnam, Nepal, Bangladesh and Australia
July 7, 2020
DECN CEO Offers Open Letter on COVID-19 Testing Highlighting Needed Support for Innovation in Testing
July 1, 2020
DECN Files Provisional Patent For GenViro! Professional COVID-19 :15 Swift Kit, Adds Enhanced Technology To Allow For Even Swifter Results
June 16, 2020
DECN Readies Its 2nd EUA Amendment With The FDA For Its GenViro! Swift Professional COVID-19 :15 Test Kit, And Also Announces Its Further Support For More And Continued Worldwide COVID-19 Testing
June 11, 2020
DECN CEO Interviewed On Vancouver's #1 News/Talk Radio Station, Discusses GenViro! Covid-19 :15 Swift Test Kit, Additional Interviews Anticipated
June 3, 2020
DECN to Publish Specific Testing Completed on its GenViro! Covid-19 :15 Swift Test Kits for Viewing by Shareholders and Other Interested Parties
May 20, 2020
Covid-19:15 Second Home Testing GenViro! Swift Kit Identified By Largest CBS Affiliate In The Country As Potential Testing Solution To Help Get Country Back To Work
May 11, 2020
DECN Strongly Questions SEC’s Unilateral Imposition Of 10-Day Trading Suspension -- Company Is Undaunted And Still Seeks Expedited FDA EUA Approval For Genviro! Swift :15 Virus Test Kit
April 26, 2020
SEC Suspension of Trading
April 24, 2020
DECN To Submit Second EUA Application For Covid-19 :15 Home Testing GenViro! Swift Kit, Reports Huge Response From Fortune 500 Companies
April 22, 2020
DECN to Provide Updates on the Progress of Our GenViro! Covid-19 Test Kits on Thursday April 23
April 20, 2020
DECN Receives Pre-EUA Acknowledgement Letter And Product Serial Number From U.S. FDA For GenViro!(TM) Covid-19 Screening Kit For Professional Use
April 6, 2020
DECN Files Finalized FDA EUA Application for Its Genviro! Covid-19 Swift Kit, Receives Notification of Acceptance From FDA After-Hours on Friday 4/3/2020
April 5, 2020
DECN to Add 2nd Covid-19 Test Kit Using Antibody/Antigen Methodology as a Determination Test for Patients Who Previously Tested Positive for Covid-19
March 24, 2020
DECN Finalizes FDA Pre-EUA Version of Its Genviro! Screening Covid-19 Swift Kit, Providing Results in 15 Seconds Using Only 1.0-2.0 Microliters Whole Blood
March 22, 2020